Last week I posted my list of 2017 predictions for the stem cell field. Today a couple of days into 2017 I’m more focused on hope than realism. What would I wish for in the stem cell and regenerative medicine arena in the coming year? More stem cell clinical trial data posted and published. There are […]
Stem cell wish list for 2017 Read More »
My colleague Leigh Turner and I today published a new paper in Cell Stem Cell documenting for the first time the American stem cell clinic arena in a comprehensive way, which we found as of February has a remarkable 570 clinic locations via 351 businesses. These numbers are way beyond the predictions of most researchers
New paper with Leigh Turner shows huge American stem cell clinic industry: 570 locations Read More »
Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind
ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP Read More »
What were the top 10 stem cell stories of the year? What were the biggest news and science headlines in the stem cell field in 2015, whether good or bad? Below are mine. What are your top 10 stem cell stories of the past year? Let us know in the comments. Organoids explode. Stem cell-based
Key stem cell stories of the year 2015 Read More »
I recently chatted with Sean Morrison, current President of ISSCR, on his goals for the Society, where the stem cell field stands today, top challenges, and the future. 2020 update: read my new interview with Sean on cell therapies for COVID-19. What are your goals for your tenure as President of ISSCR? SM: ISSCR is the
ISSCR President Sean Morrison on challenges and future of stem cell field Read More »
Professor Steven Pinker of Harvard has been making the case recently that when it comes to novel biotechnologies such as CRISPR-Cas9 that bioethics should just get out of the way. Further, he has argued that we do not need a moratorium on clinical use of CRISPR-Cas9 for human genetic modification. In fact, he says that
Why I Disagree with Steven Pinker On CRISPR Read More »
CRISPR-Cas9 gene editing technology is red-hot right now and I’ve been doing interviews with various thought leaders on it, which today includes Steven Pinker. This technology has great power for research in the lab and there are hypothetical transformative clinical applications of CRISPR too. The latter efforts could include experimental attempts at reversal of disease-causing
Steven Pinker interview: case against bioethocrats & CRISPR germline ban Read More »
The topic of heritable human genetic modification has been heating up recently. Prominent scientists, ethicists, and legal scholars have being weighing in, and there is a range of attitudes. Some favor a complete, moratorium including even lab work, while on the other end of the spectrum there are those who have a more liberal perspective. Many
Nita Farahany Interview on Human Germline Modification: Defining A Road Forward Read More »
Stemedica announced it is teaming up with UC San Diego (UCSD) to do stem cell research. This fits with an increasing trend in the stem cell arena is the teaming up of clinical partners with very different backgrounds and priorities. For instance, academic institutions are more often working together with for-profit stem cell clinics. Another branch
Muddier stem cell waters: Stemedica teams up with UCSD doc? Read More »
It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on
ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »